Patents by Inventor Moses Goddard

Moses Goddard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210016073
    Abstract: Provided herein are devices, systems, and methods for subcutaneous membrane, encapsulation chamber, or reservoir implantation comprising or employing an implantation device configured to insert a membrane, encapsulation chamber, or reservoir into a subject.
    Type: Application
    Filed: March 12, 2019
    Publication date: January 21, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, Moses Goddard, Moses Sandrof, John Mills, Megan Billings
  • Publication number: 20070071734
    Abstract: ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.
    Type: Application
    Filed: October 3, 2006
    Publication date: March 29, 2007
    Inventors: Weng Tao, David Rein, Brenda Dean, Paul Stabila, Moses Goddard
  • Patent number: 6179826
    Abstract: Implantable therapy systems are disclosed for the local and controlled delivery of a biologically active factor to the brain, spinal cord and other target regions of a subject suffering from a dibilatating condition. The method of the invention involves surgically exposing an insertion site, generally located above a predetermined treatment site (12), in a patient. A cannula (20), having an obturator (30) or dilator (104) positioned therein, is inserted at the insertion site, defining a pathway to the treatment site. In some instances, the cannula can be inserted along the path of a guidewire (102) previously positioned at the treatment site. The cannula (20) is preferably a low friction polymeric material such as polytetrafluoroethylene. The cannula (20) generally has an open proximal end for receiving the obturator (30) or dilator (104), and an open distal end, preferably a tapered end, for delivery of neurologically active factors to the treatment site (12).
    Type: Grant
    Filed: October 29, 1996
    Date of Patent: January 30, 2001
    Assignee: Brown University Research Foundation
    Inventors: Patrick Aebischer, Moses Goddard, John G. Moldauer, Paul J. Mulhauser, Anne M. Rathbun, Paul R. Sanberg, Alfred V. Vasconcellos, Nicholas F. Warner
  • Patent number: 5871487
    Abstract: A microdrive apparatus useful in human stereotactic surgery is disclosed. Such apparatus permits safe and accurate placement of a surgical instrument, such as a cannula, into a portion of the central nervous system, e.g. the brain and spinal cord, of a patient by simple mechanical operation.
    Type: Grant
    Filed: March 10, 1997
    Date of Patent: February 16, 1999
    Assignee: CytoTherpeutics, Inc.
    Inventors: Nicholas Warner, Moses Goddard, John Mills
  • Patent number: 5643286
    Abstract: The present invention is directed to microdrive apparatus useful in human stereotactic surgery. Such apparatus permits safe and accurate placement of a surgical instrument, such as a cannula, into a portion of the central nervous system, e.g. the brain and spinal cord, of a patient by simple mechanical operation.
    Type: Grant
    Filed: June 24, 1994
    Date of Patent: July 1, 1997
    Assignee: CytoTherapeutics, Inc.
    Inventors: Nicholas Warner, Moses Goddard, John Mills
  • Patent number: 5554148
    Abstract: Refillable immunoisolatory neurological therapy devices for local and controlled delivery of a biologically active factor to the brain of a patient. The devices include a cell chamber adapted for infusion with nsecretory cells and having at least one semipermeable or permselective surface across which biologically active factors secreted by the cells can be delivered to the brain. The devices also include means for introducing secretory cells into the cell chamber, and means for renewing the cells or cell medium.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: September 10, 1996
    Assignee: Brown University Research Foundation
    Inventors: Patrick Aebischer, Paul C. DiCesare, Moses Goddard, Paul J. Mulhauser
  • Patent number: 5487739
    Abstract: Implantable therapy systems are disclosed for the local and controlled delivery of a biologically active factor to the brain, spinal cord and other target regions of a subject suffering from a debilitating condition. The method of the invention involves surgically exposing an insertion site, generally located above a predetermined treatment site (12), in a patient. A cannula (20), having an obturator (30) or dilator (104) positioned therein, is inserted at the insertion site, defining a pathway to the treatment site. In some instances, the cannula can be inserted along the path of a guidewire (102) previously positioned at the treatment site. The cannula (20) is preferably a low friction polymeric material such as polytetrafluoroethylene. The cannula (20) generally has an open proximal end for receiving the obturator (30) or dilator (104), and an open distal end, preferably a tapered end, for delivery of neurologically active factors to the treatment site (12).
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: January 30, 1996
    Assignee: Brown University Research Foundation
    Inventors: Patrick Aebischer, Moses Goddard, John G. Moldauer, Paul J. Mulhauser, Anne M. Rathbun, Paul R. Sanberg, Alfred V. Vasconcellos, Nicholas F. Warner